Optinose_logo_RGB.png
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
January 18, 2024 12:00 ET | Optinose, Inc.
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and...
Optinose_logo_RGB.png
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
August 10, 2023 07:00 ET | Optinose, Inc.
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023...
Optinose_logo_RGB.png
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
May 04, 2023 07:00 ET | Optinose, Inc.
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If...
Optinose_logo_RGB.png
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2023 08:00 ET | Optinose, Inc.
YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose_logo_RGB.png
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
February 21, 2023 07:00 ET | Optinose, Inc.
YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
November 10, 2022 07:00 ET | Optinose, Inc.
Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023 Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps...
Optinose_logo_RGB.png
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
November 09, 2022 15:00 ET | Optinose, Inc.
YARDLEY, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
November 07, 2022 15:00 ET | Optinose, Inc.
YARDLEY, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
March 07, 2022 07:00 ET | Optinose, Inc.
XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug...
Optinose_logo_RGB.png
Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
July 30, 2021 08:00 ET | Optinose, Inc.
Company Expects Top-Line Results in First Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...